{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:58:50Z","timestamp":1716001130231},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Artemisinins induce drug metabolism through the activation of the pregnane X receptor (PXR)\n            <jats:italic>in vitro<\/jats:italic>\n            . Here, we report the resequencing and genotyping of\n            <jats:italic>PXR<\/jats:italic>\n            variants in 75 Vietnamese individuals previously characterized for CYP3A enzyme activity after artemisinin exposure. We identified a total of 31\n            <jats:italic>PXR<\/jats:italic>\n            variants, including 5 novel single nucleotide polymorphisms (SNPs), and we identified significantly different allele frequencies relative to other ethnic groups. A trend of significance was observed between the level of CYP3A4 induction by artemisinin and two\n            <jats:italic>PXR<\/jats:italic>\n            variants, the 8118C\u2192T (Y328Y) and 10719A\u2192G variants.\n          <\/jats:p>","DOI":"10.1128\/aac.06009-11","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T05:13:08Z","timestamp":1326863588000},"page":"2153-2157","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["<i>PXR<\/i>\n            Variants and Artemisinin Use in Vietnamese Subjects: Frequency Distribution and Impact on the Interindividual Variability of CYP3A Induction by Artemisinin"],"prefix":"10.1128","volume":"56","author":[{"given":"Rita","family":"Piedade","sequence":"first","affiliation":[{"name":"Dr. Margarete Fischer Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany"},{"name":"Drug Resistance Unit, Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Centre for Molecular and Structural Biomedicine, Institute of Biotechnology and Bioengineering (CBME\/IBB), University of Algarve, Faro, Portugal"}]},{"given":"Elke","family":"Schaeffeler","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany"}]},{"given":"Stefan","family":"Winter","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany"}]},{"given":"Sara","family":"Asimus","sequence":"additional","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany"},{"name":"Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}]},{"given":"Oliver","family":"Burk","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany"}]},{"given":"Jos\u00e9 P.","family":"Gil","sequence":"additional","affiliation":[{"name":"Drug Resistance Unit, Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Centre for Molecular and Structural Biomedicine, Institute of Biotechnology and Bioengineering (CBME\/IBB), University of Algarve, Faro, Portugal"},{"name":"Harpur College of Arts and Sciences, Department of Biological Sciences, Binghamton University, Binghamton, New York, USA"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1472-8206.2007.00471.x","article-title":"Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects","volume":"21","author":"Asimus S","year":"2007","unstructured":"AsimusS. 2007. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam. Clin. Pharmacol. 21:307\u2013316.","journal-title":"Fundam. Clin. Pharmacol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","article-title":"Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients","volume":"48","author":"Benkali K","year":"2009","unstructured":"BenkaliK. 2009. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet. 48:805\u2013816.","journal-title":"Clin. Pharmacokinet"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00228-006-0108-0","article-title":"Screening for polymorphisms in the PXR gene in a Dutch population","volume":"62","author":"Bosch TM","year":"2006","unstructured":"BoschTM. 2006. Screening for polymorphisms in the PXR gene in a Dutch population. Eur. J. Clin. Pharmacol. 62:395\u2013399.","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.009019"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/QCO.0b013e328332674a","article-title":"Progress in the development of piperaquine combinations for the treatment of malaria","volume":"22","author":"D'Alessandro U","year":"2009","unstructured":"D'AlessandroU. 2009. Progress in the development of piperaquine combinations for the treatment of malaria. Curr. Opin. Infect. Dis. 22:588\u2013592.","journal-title":"Curr. Opin. Infect. Dis"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2009.04.002"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","article-title":"Understanding the pharmacokinetics of Coartem","volume":"8","author":"Djimde A","year":"2009","unstructured":"DjimdeA LefevreG. 2009. Understanding the pharmacokinetics of Coartem. Malar. J. 8(Suppl. 1):S4.","journal-title":"Malar. J"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2005.12.008","article-title":"The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease","volume":"130","author":"Dring MM","year":"2006","unstructured":"DringMM. 2006. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130:341\u2013348, 592.","journal-title":"Gastroenterology"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1475-2875-8-196","article-title":"Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy","volume":"8","author":"Hombhanje FW","year":"2009","unstructured":"HombhanjeFW. 2009. Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malar. J. 8:196.","journal-title":"Malar. J"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.tpj.6500478","article-title":"PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients","volume":"8","author":"Hor SY","year":"2008","unstructured":"HorSY. 2008. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J. 8:139\u2013146.","journal-title":"Pharmacogenomics J"},{"key":"e_1_3_3_12_2","first-page":"1454","article-title":"Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4","volume":"29","author":"Hustert E","year":"2001","unstructured":"HustertE. 2001. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29:1454\u20131459.","journal-title":"Drug Metab. Dispos"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2370.1999.00184.x","article-title":"Mitochondrial DNA polymorphism in the Vietnamese population","volume":"26","author":"Ivanova R","year":"1999","unstructured":"IvanovaR. 1999. Mitochondrial DNA polymorphism in the Vietnamese population. Eur. J. Immunogenet. 26:417\u2013422.","journal-title":"Eur. J. Immunogenet"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2006.05.057","article-title":"Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis","volume":"131","author":"Karlsen TH","year":"2006","unstructured":"KarlsenTH. 2006. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 131:781\u2013787.","journal-title":"Gastroenterology"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70320-2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135308"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00228-007-0295-3","article-title":"Identification of NR1I2 genetic variation using resequencing","volume":"63","author":"King CR","year":"2007","unstructured":"KingCR. 2007. Identification of NR1I2 genetic variation using resequencing. Eur. J. Clin. Pharmacol. 63:547\u2013554.","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2217\/14622416.8.8.1075","article-title":"Silent SNPs: impact on gene function and phenotype","volume":"8","author":"Komar AA","year":"2007","unstructured":"KomarAA. 2007. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8:1075\u20131080.","journal-title":"Pharmacogenomics"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MPG.0b013e31818de1a8","article-title":"Nuclear pregnane X receptor single nucleotide polymorphism (-25385C\/T) is not associated with inflammatory bowel disease in pediatric patients","volume":"49","author":"Lacher M","year":"2009","unstructured":"LacherM. 2009. Nuclear pregnane X receptor single nucleotide polymorphism (-25385C\/T) is not associated with inflammatory bowel disease in pediatric patients. J. Pediatr. Gastroenterol. Nutr. 49:147\u2013150.","journal-title":"J. Pediatr. Gastroenterol. Nutr"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016600"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/ibd.20252","article-title":"Role of the PXR gene locus in inflammatory bowel diseases","volume":"13","author":"Mart\u00ednez A","year":"2007","unstructured":"Mart\u00ednezA. 2007. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm. Bowel Dis. 13:1484\u20131487.","journal-title":"Inflamm. Bowel Dis"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498250903420243"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1515\/CCLM.2010.130","article-title":"Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane\/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers","volume":"48","author":"Oliver P","year":"2010","unstructured":"OliverP LubomirovR CarcasA. 2010. Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane\/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clin. Chem. Lab. Med. 48:635\u2013639.","journal-title":"Clin. Chem. Lab. Med"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.tpj.6500299","article-title":"Genotyping of the PXR A11156C polymorphism with locked nucleic acid containing fluorogenic probes","volume":"5","author":"Op den Buijsch RA","year":"2005","unstructured":"Op den BuijschRA. 2005. Genotyping of the PXR A11156C polymorphism with locked nucleic acid containing fluorogenic probes. Pharmacogenomics J. 5:72\u201374.","journal-title":"Pharmacogenomics J"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.608660"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-08-0411","article-title":"PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients","volume":"14","author":"Sandanaraj E","year":"2008","unstructured":"SandanarajE. 2008. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin. Cancer Res. 14:7116\u20137126.","journal-title":"Clin. Cancer Res"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/592304"},{"key":"e_1_3_3_28_2","first-page":"CD007483","article-title":"Artemisinin-based combination therapy for treating uncomplicated malaria","volume":"2011","author":"Sinclair D","year":"2009","unstructured":"SinclairD ZaniB DoneganS OlliaroP GarnerP. 2009. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. 2011:CD007483.","journal-title":"Cochrane Database Syst. Rev"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328333a1dd","article-title":"The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease","volume":"20","author":"Sookoian S","year":"2010","unstructured":"SookoianS. 2010. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20:1\u20138.","journal-title":"Pharmacogenet. Genomics"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-07-1276","article-title":"Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics","volume":"13","author":"Tham LS","year":"2007","unstructured":"ThamLS. 2007. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin. Cancer Res. 13:7126\u20137132.","journal-title":"Clin. Cancer Res"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","article-title":"Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial","volume":"375","author":"Tshefu AK","year":"2010","unstructured":"TshefuAK. 2010. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375:1457\u20131467.","journal-title":"Lancet"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.actatropica.2009.05.007","article-title":"Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria","volume":"111","author":"Tun T","year":"2009","unstructured":"TunT. 2009. Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Acta Trop. 111:275\u2013278.","journal-title":"Acta Trop"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-008-0573-8","article-title":"Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam","volume":"65","author":"Veiga MI","year":"2009","unstructured":"VeigaMI. 2009. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur. J. Clin. Pharmacol. 65:355\u2013363.","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000123687","article-title":"Single nucleotide polymorphisms of the pregnane x receptor gene in Han Chinese and a comparison with other ethnic populations","volume":"81","author":"Wang XD","year":"2008","unstructured":"WangXD. 2008. Single nucleotide polymorphisms of the pregnane x receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology 81:350\u2013354.","journal-title":"Pharmacology"},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","article-title":"The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants","volume":"11","author":"Zhang J","year":"2001","unstructured":"ZhangJ. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555\u2013572.","journal-title":"Pharmacogenetics"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06009-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06009-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:15:23Z","timestamp":1645481723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.06009-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1128\/AAC.06009-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.06009-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"2011-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}